Clinical Trial Detail

NCT ID NCT03457896
Title Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors NSABP Foundation Inc
Indications

colorectal cancer

Therapies

Cetuximab + Neratinib

Neratinib + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST